177 related articles for article (PubMed ID: 34572958)
61. Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series.
Ranjan T; Howard CM; Yu A; Xu L; Aziz K; Jho D; Leonardo J; Hameed MA; Karlovits SM; Wegner RE; Fuhrer R; Lirette ST; Denning KL; Valluri J; Claudio PP
Transl Oncol; 2020 Apr; 13(4):100755. PubMed ID: 32197147
[TBL] [Abstract][Full Text] [Related]
62. Regorafenib: A Review in Metastatic Colorectal Cancer.
Dhillon S
Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.
Aljubran A; Elshenawy MA; Kandil M; Zahir MN; Shaheen A; Gad A; Alshaer O; Alzahrani A; Eldali A; Bazarbashi S
Clin Med Insights Oncol; 2019; 13():1179554918825447. PubMed ID: 30728734
[TBL] [Abstract][Full Text] [Related]
64. Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.
Gotfrit J; Vickers M; Sud S; Asmis T; Cripps C; Goel R; Hsu T; Jonker D; Goodwin R
Curr Oncol; 2017 Aug; 24(4):234-239. PubMed ID: 28874891
[TBL] [Abstract][Full Text] [Related]
65. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
66. Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer.
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H
Oncol Lett; 2018 Nov; 16(5):6589-6597. PubMed ID: 30344762
[TBL] [Abstract][Full Text] [Related]
67. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
68. Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre.
Chamberlain F; Farag S; Williams-Sharkey C; Collingwood C; Chen L; Mansukhani S; Engelmann B; Al-Muderis O; Chauhan D; Thway K; Fisher C; Jones RL; Gennatas S; Benson C
Clin Sarcoma Res; 2020; 10():1. PubMed ID: 31911828
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
70. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
71. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
[TBL] [Abstract][Full Text] [Related]
72. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
73. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
[TBL] [Abstract][Full Text] [Related]
74. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
[TBL] [Abstract][Full Text] [Related]
75. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
76. Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy.
Huemer F; Piringer G; Schlintl V; Hackl H; Rinnerthaler G; Thaler J; Greil R; Weiss L
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007814
[TBL] [Abstract][Full Text] [Related]
77. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
78. Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Grimaudo MS; Laffi A; Gennaro N; Fazio R; D'Orazio F; Samà L; Siracusano LV; Sicoli F; Renne SL; Santoro A; Bertuzzi AF
Front Oncol; 2023; 13():1190123. PubMed ID: 37324004
[TBL] [Abstract][Full Text] [Related]
79. Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.
Treiber H; von der Brelie C; Malinova V; Mielke D; Rohde V; Chapuy CI
Neurosurg Rev; 2022 Oct; 45(5):3201-3208. PubMed ID: 35725846
[TBL] [Abstract][Full Text] [Related]
80. Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma.
Pantalone MR; Rahbar A; Söderberg-Naucler C; Stragliotto G
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]